In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors

British Journal of Pharmacology

Volumn 117, Issue 8, 1996, Pages 1625-1632

  Hidaka, Kazuyuki ^a   Tada, Shoko ^a   Matsumoto, Mitsuyuki ^a   Ohmori, Junya ^a   Tasaki, Yoshikazu ^a   Nomura, Tamako ^a   Usuda, Shinji ^a   Yamaguchi, Tokio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Adenylate cyclase; Antagonist; D2 like receptors; D3 dopamine receptor; D4 dopamine receptor; GTPase; Low K(m); Selectivity; YM 43611

Indexed keywords

ADENYLATE CYCLASE; BENZAMIDE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; GUANOSINE TRIPHOSPHATASE; N (1 BENZYL 3 PYRROLIDINYL) 5 CHLORO 4 CYCLOPROPYLCARBOXAMIDO 2 METHOXYBENZAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; DRUG POTENCY; DRUG RECEPTOR BINDING; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

EID: 0029968796     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15332.x     Document Type: Article

References (41)

1. 50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
2. CHIO, C.L., HESS, G.F., GRAHAM, R.S. & HUFF, R.M. (1990). A second molecular form of D2 dopamine receptor in rat and bovine caudate nucleus. Nature, 343, 266-269.
3. CHIO, C.L., LAJINESS, M.E. & HUFF, R.M. (1994a). Activation of heterogously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol., 45, 51-60.
4. CHIO, C.L., DRONG, R.F., RILEY, D.T., GILL, G.S., SLIGHTOM, J.L. & HUFF, R.M. (1994b). D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. J. Biol. Chem., 269, 11813-11819.
5. CLARK, M.J. & MEDZIHRADSKY, F. (1987) Coupling of multiple opioid receptors to GTPase following selective receptor alkylation in brain membranes. Neuropharmacology, 26, 1763-1770.
6. DAUM, P.R., DOWNES, C.P. & YOUNG, J.M. (1983). Histamine-induced inositol phospholipid breakdown mirrors H1-receptor density in brain. Eur. J. Pharmacol., 87, 497-498.
7. EHLERT, F.J. (1988). Gallamine alosterically antagonizes muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat myocardium. J. Pharmacol. Exp. Ther., 247, 596-602.
8. GIROS, B., MARTRES, M.-P., SOKOLOFF, P. & SCHWARTZ, J.-C. (1990). cDNA cloning of the human dopaminergic D3 receptor and chromosome identification. C. R. Seances Acad. Sci. Ser. III, 311, 501-508.
9. 3H]spiperone binding on human dopamine D4 receptors. Neurosci. Lett., 186, 145-148.
10. 3 receptor antagonist, in rabbit nodose ganglion and N1E-115 neuroblastoma cells. J. Pharmacol. Exp. Ther., 263, 1127-1132.
11. IWANAMI, S., TAKASHIMA, M., HIRATA, Y., HASEGAWA, O. & USUDA, S. (1981). Synthesis and neuroleptic activity of benzamides, cis-N-(1-benzyl-2-methylpyrrolidin-3-ly)-5-chloro-2-methoxy-4-(methylamino) benzamide and related compounds. J. Med. Chem., 24, 1224-1230.
12. KAUFMAN, R.J., DAVIS, M.V., PATHAK, V.K. & HERSHEY, J.W.B. (1989). The phosphorylation state of eucaryotic initiation factor 2 alters transductional efficiency of specific mRNAs. Mol. Cell. Biol., 9, 946-958.
13. KEBABIAN, J.W. & CALNE, D.B. (1979). Multiple dopamine receptors for dopamine. Nature, 277, 93-96.
14. KREISS, D.S., BERGSTROM, D.A., GONZALEZ, A.M., HUANG, K.-X., SIBLEY, D.R. & WALTERS, J.R. (1995). Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur. J. Pharmacol., 277, 209-214.
15. LAHTI, R.A., EVANS, D.L., STRATMAN, N.C. & FIGUR, L.M. (1993). Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur. J. Pharmacol., 236, 483-486.
16. LAJINESS, M.E., CHIO, C.L. & HUFF, R.M. (1995). Signaling mechanisms of D2, D3, and D4 dopamine receptors determined in transfected cell lines. Clin. Neuropharmacol., 18, S25-S33.
17. LAZARENO, S. & ROBERTS, F.F. (1987). Measuring muscarinic antagonist potency using phosphoinositide breakdown in rat cortex slices. Br. J. Pharmacol., 92, 677P.
18. 2 receptor binding. Mol. Pharmacol., 21, 301-314.
19. LEIGEOIS, J.-F., BRUHWYLER, J., DAMES, J., ROGISTER, F., MASEREEL, B., GECZY, J. & DELARGE, J. (1995). Modulation of the clozapine structure increases its selectivity for the dopamine D4 receptor. Eur. J. Pharmacol., 273, R1-R3.
20. MARTIN, M.W., SMITH, M.M. & HARDEN, T.K. (1984). Modulation of muscarinic cholinergic receptor affinity for antagonist. J. Pharmacol. Exp. Ther., 230, 424-430.
21. MATSUMOTO, M., HIDAKA, K., TADA, S., TASAKI, K. & YAMAGUCHI, T. (1995). Full-length cDNA cloning and distribution of human dopamine D4 receptor. Mol. Brain Res., 29, 157-162.
22. 2-adrenergic drugs also bind with high affinity to a nonadrenergic site. Mol. Pharmacol., 35, 324-330.
23. MILLAN, M.J., AUDINOT, V., RIVET, J.-M., GOBERT, A., VIAN, J., PROST, J.-F., SPEDDING, M. & PEGLION, J.-L. (1994). S14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur. J. Pharmacol., 260, R3-R5.
24. MILLIGAN, G. (1988). Techniques used in the identification and analysis of function of pertussis toxin-sensitive guanine nucleotide binding proteins. Biochem. J., 255, 1-13.
25. MIZUSHIMA, S. & NAGATA, S. (1990). pEF-BOS, a powerful mammalian expression vector. Nucleic. Acids Res., 18, 5322.
26. MURRAY, P.J., HARRISON, L.A., JOHNSON, M.R., ROBERTSON, G.M., SCOPES, D.I.C., BULL, D.R., GRAHAM, E.A., HAYES, A.G., KILPATRICK, G.J., DAAS, I.D., LARGE, C., SHEEHAN, M.J., STUBBS, C.M. & TURPIN, M.P. (1995). A novel series of arylpiperazines with a high affinity and selectivity for the dopamine D3 receptor. Bioorg. Med. Chem. Lett., 5, 219-222.
27. 1C binding sites in rat frontal cortex. J. Neurochem., 47, 529-540.
28. POTTER, L.T., FERRENDELLI, C.A. & HANCHETT, H.E. (1988). Two affinity states of M1 muscarine receptors. Cell. Mol. Neurobiol., 8, 181-191.
29. PRATHER, P.L., MGGINN, T.M., ERICKSON, L.J., EVANS, C.J., LOH, H.H. & LAW, P-Y. (1994). Ability of δ-opioid receptors to interact with multiple G-proteins is independent of receptor density. J. Biol. Chem., 269, 21293-21302.
30. 1 pituitary cells and their regulation by activation of human D2 and D4 dopamine receptors. Br. J. Pharmacol., 112, 728-734.
31. 4. Neuropsychopharmacology, 7, 261-284.
32. SENOGLES, S.E., SPIEGEL, A.M., PADRELL, E., IYENGAR, R. & CARON, M.G. (1990). Specificity of receptor-G protein interactions. J. Biol. Chem., 265, 4507-4514.
33. SIBLEY, D.R. & MONSMA, F.J. (1992). Molecular biology of dopamine receptors. Trends Pharmacol. Sci., 15, 61-69.
34. SOKOLOFF, P., GIROS, B., MARTRES, M.-P., BOUTHENET, M.-L. & SCHWARTZ, J.-C. (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347, 146-151.
35. SVENSSON, K., CARLSSON, A. & WATERS, N. (1994). Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J. Neural. Transm., 95, 71-74.
36. SVENSSON, K., JOHANSSON, A.M., MAGNUSSON, T. & CARLSSON, A. (1986). (+)-AJ76 and (+)-UH232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn-Schmied. Arch. Pharmacol., 334, 234-245.
37. TANG, L., TODD, R.D., HELLER, A. & O'MALLEY, K.L. (1994a). Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J. Pharmacol. Exp. Ther., 268, 495-502.
38. TANG, L., TODD, R.D. & O'MALLEY, K.L. (1994b). Dopamine D2 and D3 receptors inhibit dopamine release. J. Pharmacol. Exp. Ther., 270, 475-479.
39. 3H]raclopride for dopamine D-2 receptor binding to rat striatum. Eur. J. Pharmacol., 173, 177-182.
40. USUDA, S., NISHIKORI, K., NOSHIRO, O. & MAENO, H. (1981), Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4- methylaminobenzamide (YM-0915-1-2) with selective antidopaminergic activity. Psychopharmacology, 73, 103-109.
41. VON TOL, H.H.M., BUNZOW, J.R., GUAN, H.-C., SUNAHARA, R.K., SEEMAN, P., NIZNIK, H.B. & CIVELLI, O. (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature, 350, 610-614.